Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept +/- Deferasirox in Transfusion-dependent Non-severe Aplastic Anemia
NCT06964971Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of luspatercept in aplastic anemia (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Hemoglobin at 12 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06964971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964971.